Articles

Found 12 Documents
Search

RITUXIMAB IODINATION PROCEDURE FOR RADIOIODINATED RITUXIMAB (131I-RITUXIMAB) PREPARATION Ramli, Martalena; Hidayat, Basuki; Sutari, Sutari; Setyowati, Sri; Susilo, Veronica Yulianti
Majalah Kedokteran Bandung Vol 51, No 2 (2019)
Publisher : Faculty of Medicine, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1864.956 KB) | DOI: 10.15395/mkb.v51n2.1595

Abstract

Rituximab is a chimeric monoclonal antibody which has specific for CD20 antigen expressed by pre-B and mature B-cells. Radiolabelled Rituximab, 131I-Rituximab, has been sucessfully used for treatment of B-Cell NHL. Due to its short shelf-life, 131I-Rituximab is commonly freshly prepared in hospitals prior to its used.  This study aimed to validate rituximab iodination procedure for 131I-Rituximab preparation in order to find the most suitable procedure to be applied in hospitals which intend to produce 131I-Rituximab in-house.  Three different methods of radiolabelling using three types of oxidizing agents, namely Iodobeads, Iodogen, and Chloramine-T were performed. Prior to the validation, radiochemical purity test and purification procedures were also validated as these procedures are critical for producing an acceptable quality of  I-Rituximab. In addition, the shelf-life of 131I-Rituximab was also studied. This study was conducted at the Centre for Radioisotope and Radiopharmaceutical Technology, Serpong during the period of July 2015 to February 2018.  The results showed that the radiochemical purity test of 131I-Rituximab could be easily performed by using instance thin layer chromatography?silica gel (ITLC-SG) in the stationary phase and 85% methanol or saline in the mobile phase. Purification of 131I-Rituximab was conducted using a Sephadex G-25 M filled column with 0.1 M PBS, pH 7.2, as the eluent that was found to be quite reliable to give 131I-Rituximab with radiochemical purity of >95% and recovery of approximately 90%. Radiolabelling efficiency performed using Iodobeads was the lowest (60%) compared to that of Iodogen and Chloramine-T (80?90%). In addition, approximately 30% of  I was retained by Iodobeads and this procedure was time consuming(~ 1 hours). It is concluded that Chloramine-T and Iodogen are better than Iodobeads as the oxidizing agent for radiolabelling of Rituximab with 131I. The radiochemical purity of 131I-Rituximab is well maintained when stored at room temperature and in 4 °C temperature up to 6 hours.Validasi Prosedur Iodinasi Rituximab untuk Preparasi131 I-RituximabValidasi proseduri odinasi rituximab untuk preparasi131I-Rituximab telah berhasil dilakukan.  Validasi ini dilakukan untuk mendapatkan prosedur yang paling sesuai yang dapat diaplikasikan untuk produksi131 I-Rituximabdi rumah sakit yang ingin memproduksi131 I-Rituximab di laboratorium mereka.  Tiga metode radiolabelling menggunakan 3 jenis oksidator Iodobeads, Iodogen, dan Chloramine-T telah divalidasi. Sebelum validasi ini, prosedur uji kemurnian radiokimia dan pemurnian divalidasi terlebih dahulu karena prosedur-prosedur ini sangat berpengaruh dalam penyediaan131 I-Rituximab dengan kualitas yang baik. Disampingitu, lama simpan131I-Rituximab juga dipelajari. Penelitan ini dilaksanakan di Pusat Teknologi Radioisotop dan Radiofarmaka, Serpong, Juli 2015?Februari 2018. Hasil penelitian memperlihatkan bahwa uji kemurnian radiokimia 131I-Rituximab dapat dilakukan dengan mudah menggunakan instance thin layer chromatography ? silica gel (ITLC-SG) sebagai fasa diam dan metanol 85% atau larutan salin sebagai fasa gerak. Pemurnian131I-Rituximab menggunakan kolom Sephadex G-25 M dan0.1 M PBS pH 7,2 sebagai eluen dapat diandalkan dan memberikan131I-Rituximab dengan kemurnian radiokimia >95% dan sekitar 90% perolehan kembali. Efisiensi penandaaan menggunakan Iodobeads didapatkan paling (60%) dibanding dengan Iodogen dan Chloramine-T (80 ? 90%). Di samping itu, sekitar 30% 131I hilang karena terikat pada Iodobeads dan prosedur ini memakan waktu yang panjang (~1 jam). Penandaan Rituximab 131I menggunakan Chloramine-T and Iodogen dapat disimpulkan lebih baik dibanding dengan menggunakan Iodobeads. Kemurnian radiokimia131I-Rituximab terjaga dengan baik pada penyimpanan selama 6 jam pada suhu kamar dan 4 °C.
Studi Dosimetri Internal Radiofarmaka Terapi Kanker Payudara 177Lu-DOTA-Trastuzumab Susyati, Susyati; Mutalib, Abdul; Muchtaridi, Muchtaridi; Ramli, Martalena; Aguswarini, Sri; Karyadi, Karyadi; Hidayat, Basuki; Massora, Stepanus
Jurnal Keselamatan Radiasi dan Lingkungan Vol 1, No 1 (2016): Juni 2016
Publisher : Pusat Teknologi Keselamatan dan Metrologi Radisasi - BATAN

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (953.371 KB)

Abstract

Pengobatan terarah berbasis imunologik (Imunoterapi) kanker payudara dengan mekanisme pengikatan reseptor HER2/neu oleh antibodi spesifik telah dikembangkan oleh para peneliti sejak tahun 80-an. Trastuzumab adalah antibodi yang pertama disetujui oleh Badan Pengawas Obat dan Makanan Amerika. Dari pemantauan diketahui bahwa pengobatan dengan trastuzumab selain berbiaya tinggi juga terjadi kardiotoksisitas dan resistensi obat. Mengantisipasi hal ini, para peneliti mulai mengembangkan trastuzumab dalam bentuk konjugat dengan suatu radionuklida (salah satunya adalah 177Lutesium), sebagai farmaka Radioimunoterapi (RIT) baru. Sebagai penerapan aspek keselamatan untuk tujuan melakukan proteksi terhadap pasien dari efek samping pemberian dosis radiasi internal yang tidak akurat, studi dosimetri internal perlu dilakukan sejak awal pengembangan farmaka RIT baru. Tujuan studi dosimetri internal pada RIT adalah memastikan pemberian dosis radiasi internal yang akurat dan aman untuk setiap individu pasien/memaksimalkan dosis radiasi ke sel-sel kanker dan meminimalkan dosis radiasi ke sel-sel normal. Radiofarmaka baru (177Lu)m-(DOTA)n-trastuzumab telah berhasil dipreparasi oleh para peneliti BATAN. Uji praklinik in vivo/uji biokinetik pada hewan coba mencit betina normal inbred substrain BALB/c paska pemberian dosis tunggal 100 µCi bolus intravena injeksi radiofarmaka 177Lu-DOTA-trastuzumab juga telah dilakukan. Ruang lingkup studi dosimetri internal yang dilakukan ini adalah melakukan penghitungan perkiraan dosis terabsorb oleh berbagai organ hewan coba berdasarkan data biokinetik hasil uji praklinik in vivo. Dari hasil penghitungan perkiraan dosis terabsorb menggunakan persamaan MIRD dengan bantuan data Fraksi absorbsi spesifik dari pustaka diketahui bahwa dosis terabsorb organ paru-paru paling tinggi diantara organ-organ lainnya, yaitu 1,5X10-2 µGy. Dengan memperhitungkan faktor bobot tipe radiasi dan faktor bobot tipe jaringan/organ (sebagaimana tercantum pada Publikasi ICRP No.103 tahun 2007), diperoleh dosis ekivalen dan dosis efektif organ paru-paru berturut-turut adalah 1,5 X 10-2 µSv dan 1,8 X 10-3 µSv. Dosis efektif seluruh tubuh hewan coba adalah 4,2 X 10-3 µSv. Data biokinetik berbagai organ hewan coba dapat juga dipakai sebagai masukan (input) pada penghitungan perkiraan dosis terabsorb berbagai organ phantom manusia menggunakan software dosimetri internal tertentu, seperti OLINDA/EXM software. Breast cancer targeted therapy which mechanism is the binding of HER2/neu receptor with specific antibodies have been developed by researchers since the 80’s. Trastuzumab is the first antibody approved by the US Food & Drug Administration. From monitoring known that treatment with trastuzumab also occur cardiotoxity and drug resistance in addition to high costs. Anticipating this, the researchers began developing trastuzumab in the conjugate form with a radionuclide (one of which is 177Lutesium) as a new pharmaceutical of Radioimmunotherapy (RIT). As the implementation of safety aspects in order to protect the patients from adverse effects of inaccurate internal radiation dose administration, internal dosimetry studies / assessment need to be done since the beginning of a new RIT pharmaceutical development. The objective of internal dosimetry study at RIT is to ensure accurate and safe internal radiation dose administration for each individual patients / to maximize the radiation dose to the cancer cells and minimize the radiation dose to the normal cells. The new RIT pharmaceutical 177Lu-DOTA-trastuzumab has been successfully prepared by BATAN researchers.  In vivo preclinical trials/biokinetic testing in normal female mice inbred substrain BALB/c after administration of a single dose 100 μCi of bolus intravenous 177Lu-DOTA-trastuzumab radiopharmaceutical injection also been conducted. The scope of internal dosimetry studies conducted was absorbed dose calculation estimation of the various experimental animals organs based on biokinetic data of in vivo preclinical trials. Calculation estimation of Absorbed Dose using the MIRD (Medical Internal Radiation Dose) equation with the aid of SAFs (Specific absorbed fractions) data from reference known that Absorbed Dose of lungs organ is highest among other organs ie. 1,5 X 10-2µGy. Taking into account of recommended radiation weighting factors and tissue / organ weighting factors (as stated in ICRP Publication #103, 2007) obtained equivalent dose and effective dose of lungs organ is 1,5 X 10-2 μSv and 1,8 X 10-3μSv respectively. The whole body effective dose of experimental animal is 4,2 X 10-3 μSv. The biokinetic-test results data of the various experimental animal organs can also be used as an input on the Absorbed dose calculation estimation of the various human phantom organs using certain internal dosimetry software (one example is OLINDA/EXM software).
Generalized Lymphadenopathy due to Chronic Lymphocytic Leukemia (CLL) : 18F-FDG PET Imaging Hidayat, Basuki; Hutomo, Febby; Yudistiro, Ryan; Mulyanto, Ivana D.; Budiawan, Hendra; Masjhur, Johan S.
Journal of Medicine and Health Vol 1, No 3 (2016)
Publisher : Maranatha Christian University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Lymphadenopaty is a common clinical finding with a broad differential diagnosis, withCarcinoma of Unknown Primary (CUP) as one of it’s most common causes. Flourine-18 fluoro-2 deoxy glucose (18F- FDG) positron emission tomography (PET) is a Nuclear Medicinescintigraphy procedure commonly used to localize suspected a primary lesion by depicting ametabolic status. However, in the expertise of 18F FDG PET study, clinical finding andepidemiologic data must be considered to get a better conclusion. We describe 18F-FDG PETstudy in the presence of generalized lymphadenopathy due to chronic lymphocytic leukemia(CLL), a rare disease which is initially suspected of having CUP.Keywords: 18F-FDG PET, lymphadenopathy, lymphoma, leukemia
Roles of Microwave Oven in Preparing Microbiological Growth Media Prijana, Christian; Mulyana, Yanti; Hidayat, Basuki
Althea Medical Journal Vol 3, No 1 (2016)
Publisher : Althea Medical Journal

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (677.459 KB)

Abstract

Background: Sterilization of a growth medium before being utilized is a very important step in a microbiology laboratory. The common method for this purpose is by using the autoclave. However, autoclaving takes more time. To overcome this limitation, we tried to use the microwave oven. The aim of this study was to evaluate the ability of microwave oven in preparing the growth media.Methods: This was a laboratory experimental study conducted at Microbiology Laboratory, Faculty of Medicine, Universitas Padjadjaran, from October to November 2014. The growth media used were: MacConkey agar, in petri dishes, inoculated with Escherichia coli; Sabouraud agar, in petri dishes, inoculated with Candida albicans; Kligler iron agar (KIA), in reaction tubes, inoculated with Escherichia coli and Salmonella Typhi; Simmons citrate agar, in reaction tubes, inoculated with Klebsiella pneumoniae; Mueller-Hinton (M-H) broth, in reaction tubes, inoculated with Escherichia coli; and Motility Indole Urea (MIU) semisolid agar, in reaction tubes, inoculated with Proteus sp.The media would be heated by microwave for 1, 2, and 3 minutes. Results: From the total 54 dishes/tubes of various microwave-sterilized media, contaminations were only seen at 5 dishes/tubes. Most of the media, except the one-minute-heated Mueller-Hinton broth, were sterilized more than half dishes/tubes. The identification function of all media in this study was performed well. Conclusions: The utilization of microwave oven as an alternative sterilizing apparatus for microbiological growth media is very potential, particularly for two and three minutes duration of heating. [AMJ.2016;3(1):1–5]DOI: 10.15850/amj.v3n1.469
PERANCANGAN HEWAN COBA MODEL UNTUK KARSINOMA PAYUDARA HER-2 POSITIF MENGGUNAKAN AGEN IMUNOSUPRESAN Hidayat, Basuki; Massora, Stepanus; Ramli, Martalena; Susilo, Veronika Yulianti; Arianto, Agus; Masjhur, Johan S.
Majalah Kedokteran Bandung Vol 48, No 1 (2016)
Publisher : Faculty of Medicine, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (441.256 KB)

Abstract

Pengembangan obat terapi keganasan di Indonesia sering kali terkendala karena ketidakmampuan menyediakan hewan model untuk uji preklinis. Hewan model tersebut adalah hewan model dengan massa keganasan yang mempunyai karakteristik khusus, bukan sekedar dengan massa tumor. Pada umumnya untuk tujuan tersebut digunakan hewan model yang tidak mempunyai daya tahan tubuh dan dipelihara dalam lingkungan yang steril. Fasilitas sistem perkandangan yang steril ini yang belum ada di Indonesia. Tujuan penelitian ini mengembangkan metode penyediaan hewan model mencit pengganti nude mice dengan daya tahan tubuh yang rendah, tetapi mampu hidup dalam lingkungan fasilitas pemeliharaan yang tidak steril. Penelitian dilakukan di Laboratorium Hewan dan Laboratorium Sitogenetik Pusat Teknologi Radioisotop dan Radiofarmaka, Batan, Serpong sejak bulan Juli sampai November 2014. Galur sel SKBR-3 diinokulasi pada 2 kelompok mencit sehat (Mus musculus) strain Balb/c, yaitu kelompok perlakuan dan kontrol, masing-masing 8 ekor. Cyclosporine A, agen penurun daya tahan tubuh hanya diberikan pada kelompok perlakuan sebelum dan setelah inokulasi. Pada kedua kelompok, pertumbuhan tumor secara makroskopik tidak terlihat di tempat inokulasi, tetapi tampak perbedaan bermakna antara kelompok perlakuan dan kontrol pada kadar leukosit (p:0,01), limfosit (p:0,01), monosit (p:0,01), dan segmen neutrofil (p:0,01). Pada 2 mencit kelompok perlakuan didapatkan gambaran sel degenerasi bengkak keruh di hati. Metode ini terbukti dapat menurunkan daya tahan tubuh hewan coba mencit (Mus musculus) strain Balb/c, walaupun belum mampu menumbuhkan keganasan. [MKB. 2016;48(1):39?44]Kata kunci: Ca payudara HER2 positif, hewan coba model onkologiDesigning Animal Models for HER2 Positive Breast Cancer Using Immunosuppressive AgentAbstractThe development of therapeutic drug for malignancy in Indonesia is often constrained because of the inability to provide animal models for preclinical study. These animal models are an animal model with a malignancy mass which have special characteristics, not just the tumor mass. Animal models that are usually used for this purpose is immunodeficient animals. This animal must be kept in sterile animal care, but the facility is not readily available in Indonesia. The purpose of this study was to develop a method for providing an animal model of nude mice replacement that has fairly low immunity but are still able to live in non-sterile animal care facilities. The study was conducted at the Laboratory Animal and Cytogenetics, Center for Radioisotope and Radiopharmaceuticals Technology, Batan, Serpong in the period of July to November 2014. SKBR-3 cell lines were inoculated on two groups of immunocompetent mice (Mus musculus) strain Balb/c, namely the treatment group (n=8) and controls (n=8). Cyclosporine A as an immunosupressan agent was given only to the treatment group before and after SKBR 3 inoculation. No macroscopically visible tumor growth at the site of inoculation in both of groups. There was a significant difference between the treatment group and the control group in leukocyte levels (p: 0.01), lymphocytes (p: 0.01), monocytes (p: 0.01), and neutrophil segments (p: 0.01). Two treatment groups of mice obtained cloudy degeneration in the liver. This method has significantly reduced the immunity of mice (Mus musclus) strain Balb/c but still cannot grow malignancies in experimental animals. [MKB. 2016;48(1):39?44]Key words: HER2 positive breast cancer, oncology animal models DOI: 10.15395/mkb.v48n1.732
Generalized Lymphadenopathy due to Chronic Lymphocytic Leukemia (CLL) : 18F-FDG PET Imaging Hidayat, Basuki; Hutomo, Febby; Yudistiro, Ryan; Mulyanto, Ivana D.; Budiawan, Hendra; Masjhur, Johan S.
Journal of Medicine & Health Vol 1 No 3 (2016)
Publisher : Universitas Kristen Maranatha

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (222.033 KB) | DOI: 10.28932/jmh.v1i3.520

Abstract

Lymphadenopaty is a common clinical finding with a broad differential diagnosis, withCarcinoma of Unknown Primary (CUP) as one of it’s most common causes. Flourine-18 fluoro-2 deoxy glucose (18F- FDG) positron emission tomography (PET) is a Nuclear Medicinescintigraphy procedure commonly used to localize suspected a primary lesion by depicting ametabolic status. However, in the expertise of 18F FDG PET study, clinical finding andepidemiologic data must be considered to get a better conclusion. We describe 18F-FDG PETstudy in the presence of generalized lymphadenopathy due to chronic lymphocytic leukemia(CLL), a rare disease which is initially suspected of having CUP.Keywords: 18F-FDG PET, lymphadenopathy, lymphoma, leukemia
STUDI KARAKTERISTIK LAHAN PARKIR DI RUMAH SAKIT MITRA KELUARGA CIBUBUR Hidayat, Basuki; Sylviana, Rika; Yulius, Elma
BENTANG : Jurnal Teoritis dan Terapan Bidang Rekayasa Sipil Vol 4 No 2 (2016): BENTANG Jurnal Teoritis dan Terapan Bidang Rekayasa Sipil
Publisher : Universitas Islam 45 Bekasi

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (415.361 KB)

Abstract

Masalah parkir kendaraan bermotor di Rumah Sakit Mitra Keluarga Cibubur saat ini, berhubungan erat dengan kebutuhan ruang parkir, sehingga dampak yang timbul akibat parkir kendaraan bermotor yang tidak teratur akan mengganggu kegiatan lainnya.Gambaran permasalahan parkir didapat melalui survai yang bertujuan untuk memaparkan data dari objek penelitian dan menganalisanya secara sistematis sehingga dapat mengetahui secara tepat permasalahan yang ada dalam menyelesaikan permasalahan tersebut, kemudian dilakukan pengolahan data menggunakan Microsoft Excel. Dari hasil survai yang dilakukan selama 7 hari dengan waktu pengamatan 12 jam/hari diperoleh volume parkir mobil maksimum 346 kendaraan dan 262 kendaraan untuk volume parkir motor, akumulasi parkir mobil maksimum 111 kendaraan/jam dan 80 kendaraan/jam untuk akumulasi parkir motor, indeks parkir mobil maksimum pada hari Minggu sebesar 38,58% dan 30,62% untuk indeks parkir motor, durasi parkir mobil yang paling lama yaitu selama dua jam atau 36,88% dari kendaraan yang parkir dan dua jam atau 37,20% dari kendaraan yang parkir untuk durasi parkir motor, pergantian parkir (turn over parking) mobil tertinggi pada hari Minggu pergantian parkir sebanyak 1,48 kendaraan/petak. Pergantian parkir (turn over parking) motor tertinggi terjadi pada hari Minggu, dengan pergantian parkir sebanyak 1,24 kendaraan/petak. Lahan parkir yang disediakan Rumah Sakit Mitra Keluarga Cibubur belum diperlukan penambahan lahan parkir pada tahun ini. Kata kunci: volume parkir, akumulasi parkir, indeks parkir, durasi parkir dan pergantian parkir (turn over parking)
CONSTRUCTION OF AN EXPRESSION VECTOR BASED ON PCDNA3.1(+) EXPRESSING JEMBRANA DISEASE VRIUS ENV-TM SUBUNIT GENE IN EUKARYOTIC SYSTEM Kusumawati, Asmarani; Widada, Joannes Sri; Hidayat, Basuki
Jurnal Sain Veteriner Vol 22, No 1 (2004): Juli
Publisher : Fakultas Kedokteran Hewan Universitas Gadjah Mada bekerjasama dengan PB PDHI

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1482.959 KB) | DOI: 10.22146/jsv.439

Abstract

.
Uji Preklinis 177Lu-DOTA-Trastuzumab: Radiofarmaseutika Potensial untuk Terapi Kanker Payudara HER-2 Positif RAMLI, MARTALENA; HIDAYAT, BASUKI; AGUSWARINI, SRI; KARYADI, KARYADI; ARDIYATNO, CAHYA NOVA; SUBUR, HAMMAD; HUMANI, TITIS SEKAR; RITAWIDYA, RIEN; MUTALIB, ABDUL; MASJHUR, JOHAN
JURNAL ILMU KEFARMASIAN INDONESIA Vol 11 No 2 (2013): JIFI
Publisher : Fakultas Farmasi Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (520.916 KB)

Abstract

Radiofarmaka 177Lu-(1,4,7,10-tetraazacyclododecane-N,N’,N”,N”’-tetra acetic acid)-trastuzumab (177Lu-DOTA-trastuzumab), berbasis antihuman epithelial receptor type 2 (HER-2) antibodi monoklonal, yang diharapkan potensial untuk diagnosis dan terapi kanker payudara positif HER-2, dengan kemurnian radiokimia besar dari 99% telah berhasil dipreparasi. Uji preklinis yang dimaksudkan untuk mendapatkan data dasar sebelum pelaksanaan uji klinis dan khususnya untuk melihat efektifitas 177Lu-DOTA-trastuzumab dalam membunuh sel kanker yang mengekspresikan HER-2, telah berhasil dilakukan. Data dasar tersebut diantaranya adalah data clearance, citra dengan gamma kamera dan data hasil uji sitoksisitas. Hasil uji clearance memperlihatkan bahwa ekskresi radioaktif setelah pemberian 177Lu-DOTA-trastuzumab pada tikus sehat lebih cepat melalui urin dibandingkan dengan eksresi melalui feses. Hasil pencitraan dengan kamera gamma pada tikus normal 144 jam setelah pemberian 177Lu-DOTA-trastuzumab memperlihat adanya residu radioaktif di daerah hati (< 5%, berdasarkan hasil uji biodistribusi). Residu ini lebih rendah jika dibandingkan dengan residu radioaktif pada hati yang dilaporkan untuk 111In-NSL-trastuzumab. Walaupun residu radioaktif ini relatif rendah, tetapi harus tetap menjadi perhatian yang serius pada saat 177Lu-DOTA-trastuzumab akan digunakan pada pasien penderita kanker. Uji sitotoksisitas memperlihatkan 177Lu-DOTA-trastuzumab jauh lebih efektif dalam membunuh sel kanker positif HER-2 (SKOV-3 cell lines) dibandingkan dengan trastuzumab tidak bertanda.
Roles of Microwave Oven in Preparing Microbiological Growth Media Prijana, Christian; Mulyana, Yanti; Hidayat, Basuki
Althea Medical Journal Vol 3, No 1 (2016)
Publisher : Althea Medical Journal

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (677.459 KB)

Abstract

Background: Sterilization of a growth medium before being utilized is a very important step in a microbiology laboratory. The common method for this purpose is by using the autoclave. However, autoclaving takes more time. To overcome this limitation, we tried to use the microwave oven. The aim of this study was to evaluate the ability of microwave oven in preparing the growth media.Methods: This was a laboratory experimental study conducted at Microbiology Laboratory, Faculty of Medicine, Universitas Padjadjaran, from October to November 2014. The growth media used were: MacConkey agar, in petri dishes, inoculated with Escherichia coli; Sabouraud agar, in petri dishes, inoculated with Candida albicans; Kligler iron agar (KIA), in reaction tubes, inoculated with Escherichia coli and Salmonella Typhi; Simmons citrate agar, in reaction tubes, inoculated with Klebsiella pneumoniae; Mueller-Hinton (M-H) broth, in reaction tubes, inoculated with Escherichia coli; and Motility Indole Urea (MIU) semisolid agar, in reaction tubes, inoculated with Proteus sp.The media would be heated by microwave for 1, 2, and 3 minutes. Results: From the total 54 dishes/tubes of various microwave-sterilized media, contaminations were only seen at 5 dishes/tubes. Most of the media, except the one-minute-heated Mueller-Hinton broth, were sterilized more than half dishes/tubes. The identification function of all media in this study was performed well. Conclusions: The utilization of microwave oven as an alternative sterilizing apparatus for microbiological growth media is very potential, particularly for two and three minutes duration of heating. [AMJ.2016;3(1):1–5]DOI: 10.15850/amj.v3n1.469